1. Home
  2. TDUP vs IVA Comparison

TDUP vs IVA Comparison

Compare TDUP & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ThredUp Inc.

TDUP

ThredUp Inc.

SELL

Current Price

$2.31

Market Cap

745.9M

ML Signal

SELL

Logo Inventiva S.A. American Depository Shares

IVA

Inventiva S.A. American Depository Shares

HOLD

Current Price

$3.17

Market Cap

737.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TDUP
IVA
Founded
2009
2011
Country
United States
France
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
745.9M
737.1M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
TDUP
IVA
Price
$2.31
$3.17
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
12
Target Price
$7.24
★ $15.20
AVG Volume (30 Days)
1.8M
★ 2.3M
Earning Date
11-04-2026
09-28-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 75.36
N/A
EPS
N/A
★ N/A
Revenue
★ $310,813,000.00
N/A
Revenue This Year
$11.57
N/A
Revenue Next Year
$10.33
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 19.53
N/A
52 Week Low
$2.09
$2.82
52 Week High
$9.47
$7.98

Technical Indicators

Market Signals
Indicator
TDUP
IVA
Relative Strength Index (RSI) 42.71 38.29
Support Level $2.09 N/A
Resistance Level $2.79 $4.80
Average True Range (ATR) 0.12 0.23
MACD 0.06 -0.01
Stochastic Oscillator 49.88 33.69

Price Performance

Historical Comparison
TDUP
IVA

About TDUP ThredUp Inc.

ThredUp Inc is an online resale platform for apparel, shoes, and accessories. The company's marketplaces have enabled buyers in the United States ("U.S.") to browse and purchase resale items principally for apparel, shoes, and accessories across a range of price points. The company's revenue is principally from the sale of secondhand apparel, shoes, and accessories on behalf of sellers.

About IVA Inventiva S.A. American Depository Shares

Inventiva SA is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with unmet medical needs.

Share on Social Networks: